| 1.61 0.02 (1.26%) | 12-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.05 |
1-year : | 2.4 |
| Resists | First : | 1.75 |
Second : | 2.05 |
| Pivot price | 1.57 |
|||
| Supports | First : | 1.51 |
Second : | 1.37 |
| MAs | MA(5) : | 1.58 |
MA(20) : | 1.58 |
| MA(100) : | 1.52 |
MA(250) : | 1.33  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 52.7 |
D(3) : | 52.4 |
| RSI | RSI(14): 56.5 |
|||
| 52-week | High : | 1.75 | Low : | 0.85 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ OPK ] has closed below upper band by 11.1%. Bollinger Bands are 52.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.76 - 1.77 | 1.77 - 1.78 |
| Low: | 1.58 - 1.59 | 1.59 - 1.6 |
| Close: | 1.6 - 1.61 | 1.61 - 1.62 |
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
Thu, 12 Dec 2024
Charles Schwab Investment Management Inc. Sells 835,569 Shares of OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
Wed, 11 Dec 2024
Opko health CEO Phillip Frost purchases $781,050 in shares - Investing.com
Wed, 11 Dec 2024
Is OPKO Health (OPK) the Best NASDAQ Penny Stock to Buy Right Now? - Yahoo Finance
Tue, 10 Dec 2024
NextPlat Gains e-Commerce Access to Over 340 Million Consumers with Launch on JD.Com, China's Largest Online Retailer - Quantisnow
Tue, 10 Dec 2024
NextPlat Secures Major Deal: Approved to Sell OPKO Health Products on JD.com's Massive E-commerce Platform - StockTitan
Sun, 08 Dec 2024
OPKO Health (NASDAQ:OPK) investors are sitting on a loss of 59% if they invested three years ago - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 673 (M) |
| Shares Float | 272 (M) |
| Held by Insiders | 54.4 (%) |
| Held by Institutions | 28 (%) |
| Shares Short | 95,640 (K) |
| Shares Short P.Month | 92,940 (K) |
| EPS | -0.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.05 |
| Profit Margin | -18.8 % |
| Operating Margin | -61.8 % |
| Return on Assets (ttm) | -9 % |
| Return on Equity (ttm) | -9.4 % |
| Qtrly Rev. Growth | -2.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.05 |
| EBITDA (p.s.) | -0.32 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -177 (M) |
| Levered Free Cash Flow | -110 (M) |
| PE Ratio | -8.48 |
| PEG Ratio | 0 |
| Price to Book value | 0.78 |
| Price to Sales | 1.52 |
| Price to Cash Flow | -6.11 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|